Characteristics of screening detected prostate cancer in men 50 to 66 years old with 3 to 4 ng./Ml. Prostate specific antigen

Journal of Urology

Volumn 159, Issue 3, 1998, Pages 899-903

  Lodding, P ^a   Aus, G ^a   Bergdahl, S ^a   Frosing R ^a   Lilja, H ^a   Pihl, C G ^a   Hugosson, J ^a  

^a NONE

Author keywords

Biopsy; Prostate specific antigen; Prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY; TUMOR VOLUME;

EID: 0031883878     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)63766-2     Document Type: Article

References (30)

1. Bangma, C. H., Kranse, R., Blijenberg, B. G. and Schröder, F. H.: The value of screening tests in the detection of prostate cancer. Part I: results of a retrospective evaluation of 1726 men. Urology, 46: 773, 1995.
2. Mettlin, C., Murphy, G. P., Lee, F., Littrup, P. J., Chesley, A., Babaian, R., Badalament, R., Kane, R. A. and Mostofi, F. K., for the investigators of the American Cancer Society-National Prostate Cancer Detection Project: Characteristics of prostate cancers detected in a multimodality early detection program. Cancer, 72: 1701, 1993.
3. Smith, D. S. and Catalona, W. J.: The nature of prostate cancer detected through prostate specific antigen based screening. J. Urol., 152: 1732, 1994.
4. Labrie, F., Candas, B., Cusan, L., Gomez, J.-L., Diamond, P., Suburo, R. and Lemay, M.: Diagnosis of advanced or noncurable prostate cancer can be practically eliminated by prostate-specific antigen. Urology, 47: 212, 1996.
5. Scardino, P. T., Weaver, R. and Hudson, M. A.: Early detection of prostate cancer. Hum. Path., 23: 211, 1992.
6. Oesterling, J. E., Suman, V. J., Zincke, H. and Bostwick, D. G.: PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol. Clin. N. Amer., 20: 687, 1993.
7. Epstein, J. I., Walsh, P. C., Carmichael, M. and Brendler, C. B.: Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. J.A.M.A., 271: 368, 1994.
8. Ohori, M., Wheeler, T. M., Dunn, J. K., Stamey, T. A. and Scardino, P. T.: The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J. Urol., 152: 1714, 1994.
9. Humphrey, P. A., Keetch, D. W., Smith, D. S., Shepherd, D. L. and Catalona, W. J.: Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J. Urol., 155: 816, 1996.
10. Lerner, S. E., Seay, T. M., Blute, M. L., Bergstralh, E. J., Barret, D. and Zincke, H.: Prostate specific antigen detected prostate cancer (clinical stage T1c): an interim analysis. J. Urol., 155: 821, 1996.
11. Noldus, J. and Stamey, T. A.: Histological characteristics of radical prostatectomy specimens in men with a serum prostate specific antigen of 4 ng./ml. or less. J. Urol., 155: 441, 1996.
12. Stamey, T. A.: Making the most of six systematic sextant biopsies. Urology, 45: 2, 1995.
13. Terris, M. K., McNeal, J. E. and Stamey, T. A.: Detection of clinically significant prostate cancer by transrectal ultrasound-guided systematic biopsies. J. Urol., 148: 829, 1992.
14. Catalona, W. J., Smith, D. S. and Ornstein, D. K.: Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng./ml. and benign prostate examination. Enhancement of specificity with free PSA measurements. J.A.M.A., 277: 1452, 1997.
15. Smith, D. S., Catalona, W. J. and Herschman, J. D.: Longitudinal screening for prostate cancer with prostate-specific antigen. J.A.M.A., 276: 1309, 1996.
16. Colberg, J. W., Smith, D. S. and Catalona, W. J.: Prevalence and pathological extent of prostate cancer in men with prostate specific antigen levels of 2.9 to 4.0 ng./ml. J. Urol., 149: 507, 1993.
17. Presti, J. C., Hovey, R., Carroll, P. R. and Shinohara, K.: Prospective evaluation of prostate specific antigen and prostate specific antigen density in the detection of nonpalpable and stage T1c carcinoma of the prostate. J. Urol., 156: 1685, 1996.
18. van Cangh, P. J., de Nayer, P., de Vischer, L., Sauvage, P., Tombal, B., Lorge, F., Wese, F. X. and Opsomer, R.: Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) in the diagnostic gray zone of 1.8 to 10 ng./ml. total PSA. Urology, 48: 67, 1996.
19. Prestigiacomo, A. F. and Stamey, T. A.: Can free and total prostate specific antigen and prostatic volume distinguish between men with negative and positive systematic ultrasound guided prostate biopsies? J. Urol., 157: 189, 1997.
20. Oesterling, J. E., Jacobsen, S. J., Chute, C. G., Guess, H. A., Girman, C. J., Panser, L. A. and Lieber, M. M.: Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. J.A.M.A., 270: 860, 1993.
21. McNeal, J. E.: Cancer volume and site of origin of adenocarcinoma in the prostate: relationship to local and distant spread. Hum. Path., 23: 258, 1992.
22. Schmid, H.-P., McNeal, J. E. and Stamey, T. A.: Observations on the doubling time of prostate cancer. The use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. Cancer, 71: 2031, 1993.
23. Epstein, J. L, Carmichael, M., Partin, A. W. and Walsh, P. C.: Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of follow-up. J. Urol., 149: 1478, 1993.
24. Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A. and Whittemore, A. S.: Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer, 71: 933, 1993.
25. Dietrick, D. D., McNeal, J. E. and Stamey, T. A.: Core cancer length in ultrasound-guided systematic sextant biopsies: a preoperative evaluation of prostate cancer volume. Urology, 45: 987, 1995.
26. Irwin, M. B. and Trapasso, J. G.: Identification of insignificant prostate cancers: analysis of preoperative parameters. Urology, 44: 862, 1994.
27. Weldon, V. E., Tavel, F. R., Neuwirth, H. and Cohen, R.: Failure of focal prostate cancer on biopsy to predict focal prostate cancer: the importance of prevalence. J. Urol., 154: 1074, 1995.
28. Cupp, M. R., Bostwick, D. G., Meyers, R. P. and Oesterling, J. E.: The volume of prostate cancer in the biopsy specimen cannot reliably predict the quantity of cancer in the radical prostatectomy specimen on an individual basis. J. Urol., 153: 1543, 1995.
29. Bruce, R. G., Rankin, W. L., Cibull, M. L., Rayens, M. K., Banks, E. R. and Wood, D. P., Jr.: Single focus of adenocarcinoma in the prostate biopsy specimen is not predictive of the pathologic stage of disease. Urology, 48: 75, 1996.
30. Kupelian, P., Katcher, J., Levin, H., Zippe, C. and Klein, E.: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology, 48: 249, 1996.